累积静脉伏立康唑剂量对血液病患者肾功能的影响。
Effect of Cumulative Intravenous Voriconazole Dose on Renal Function in Hematological Patients.
机构信息
Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
出版信息
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00507-18. Print 2018 Sep.
Abstract
Intravenous voriconazole (VRC) is formulated by the incorporation of sulfobutylether-β-cyclodextrin (SBECD), which may accumulate to adversely affect renal function. However, the effect of long-term use of intravenous VRC on renal function is unclear. Our retrospective analysis of data confirmed that worsening of renal function was significantly associated with a cumulative dose of intravenous VRC (≥400 mg/kg), suggesting that a higher cumulative dose of intravenous VRC is a risk factor for renal dysfunction.
摘要
静脉注射伏立康唑（VRC）通过磺丁基醚-β-环糊精（SBECD）的加入来配制，这可能会蓄积并对肾功能产生不良影响。然而，长期使用静脉 VRC 对肾功能的影响尚不清楚。我们对数据的回顾性分析证实，肾功能恶化与静脉 VRC 的累积剂量（≥400mg/kg）显著相关，提示静脉 VRC 的更高累积剂量是肾功能障碍的一个危险因素。
相似文献
1
Effect of Cumulative Intravenous Voriconazole Dose on Renal Function in Hematological Patients.累积静脉伏立康唑剂量对血液病患者肾功能的影响。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00507-18. Print 2018 Sep.
2
Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.在肾功能损害的血液学患者中，用磺丁基醚β-环糊精配制的静脉注射伏立康唑的治疗药物监测与安全性
Mycoses. 2016 Oct;59(10):644-51. doi: 10.1111/myc.12517. Epub 2016 Jun 21.
3
Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: A systematic review.基线肾功能损害患者静脉用伏立康唑治疗后肾功能恶化：系统评价。
Int J Antimicrob Agents. 2015 Oct;46(4):362-6. doi: 10.1016/j.ijantimicag.2015.05.023. Epub 2015 Jul 22.
4
Evaluation of intravenous voriconazole in patients with compromised renal function.评估肾功能受损患者的静脉用伏立康唑。
BMC Infect Dis. 2013 Jan 16;13:14. doi: 10.1186/1471-2334-13-14.
5
Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.终末期肾衰竭患者在两种血液透析系统和血液透析滤过治疗中使用磺丁基醚-β-环糊精和伏立康唑的药代动力学。
Antimicrob Agents Chemother. 2010 Jun;54(6):2596-602. doi: 10.1128/AAC.01540-09. Epub 2010 Apr 5.
6
Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.伏立康唑在肾功能受损受试者中的药代动力学、安全性及耐受性：两项前瞻性、多中心、开放标签、平行组志愿者研究
Clin Drug Investig. 2008;28(7):409-20. doi: 10.2165/00044011-200828070-00002.
7
Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.基线肾功能不全和念珠菌血症患者中伏立康唑的安全性和耐受性。
Antimicrob Agents Chemother. 2012 Jun;56(6):3133-7. doi: 10.1128/AAC.05841-11. Epub 2012 Mar 26.
8
Administration of voriconazole in patients with renal dysfunction.肾功能障碍患者伏立康唑的给药。
Clin Infect Dis. 2012 Apr;54(7):913-21. doi: 10.1093/cid/cir969. Epub 2012 Jan 19.
9
Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).磺丁基醚-β-环糊精（SBECD）的基础和临床药理学评价。
J Pharm Sci. 2010 Aug;99(8):3291-301. doi: 10.1002/jps.22109.
10
Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.接受持续肾脏替代治疗的重症患者中磺丁基醚-β-环糊精（SBECD）蓄积及伏立康唑药代动力学的评估。
Crit Care. 2015 Feb 3;19(1):32. doi: 10.1186/s13054-015-0753-8.
引用本文的文献
1
Effects of postoperative antifungal therapy on the recurrence of Aspergillus infection after pulmonary aspergilloma resection: a prospective, randomized, controlled, single-center, 24-month, open-label, parallel group trial.术后抗真菌治疗对肺曲菌球切除术后曲霉菌感染复发的影响：一项前瞻性、随机、对照、单中心、为期24个月的开放标签平行组试验。
BMC Infect Dis. 2025 Jul 3;25(1):895. doi: 10.1186/s12879-025-11267-w.
2
Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure.抗病毒药物治疗 COVID-19 与急性肾衰竭的关联。
In Vivo. 2024 Jul-Aug;38(4):1841-1846. doi: 10.21873/invivo.13637.
3
Clinical application of voriconazole in pediatric patients: a systematic review.伏立康唑在儿科患者中的临床应用：系统评价。
Ital J Pediatr. 2024 Jun 9;50(1):113. doi: 10.1186/s13052-024-01684-z.
4
Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy.静脉用吡仑帕奈作为日本癫痫患者口服制剂的替代选择。
Epilepsia Open. 2023 Dec;8(4):1369-1382. doi: 10.1002/epi4.12804. Epub 2023 Aug 30.
5
Factors influencing plasma concentration of voriconazole and voriconazole- N-oxide in younger adult and elderly patients.影响年轻成人和老年患者伏立康唑及伏立康唑 - N - 氧化物血浆浓度的因素。
Front Pharmacol. 2023 Feb 13;14:1126580. doi: 10.3389/fphar.2023.1126580. eCollection 2023.
6
A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.有效警示还是临床传闻：多中心匹配队列中肾功能损害患者使用瑞德西韦的安全性结局评估。
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.02290-20.
7
and Mechanisms of Antifungal Resistance.以及抗真菌耐药机制。
Antibiotics (Basel). 2020 Jun 9;9(6):312. doi: 10.3390/antibiotics9060312.
8
Resveratrol Delivery from Implanted Cyclodextrin Polymers Provides Sustained Antioxidant Effect on Implanted Neural Probes.植入型环糊精聚合物递送白藜芦醇对植入式神经探针提供持续的抗氧化作用。
Int J Mol Sci. 2020 May 19;21(10):3579. doi: 10.3390/ijms21103579.
9
Extrapolating Antifungal Animal Data to Humans - Is it reliable?将抗真菌动物实验数据外推至人类——这可靠吗？
Curr Fungal Infect Rep. 2020 Mar;14(1):50-62. doi: 10.1007/s12281-020-00370-x. Epub 2020 Jan 16.
本文引用的文献
1
Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.血清C反应蛋白水平影响异基因造血细胞移植受者的血浆伏立康唑谷浓度。
Leuk Lymphoma. 2017 Nov;58(11):2731-2733. doi: 10.1080/10428194.2017.1300897. Epub 2017 Mar 17.
2
Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.兰索拉唑和雷贝拉唑对异基因造血细胞移植受者伏立康唑血药谷浓度的不同影响。
Ann Hematol. 2016 Oct;95(11):1845-51. doi: 10.1007/s00277-016-2782-z. Epub 2016 Aug 18.
3
Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.在肾功能损害的血液学患者中，用磺丁基醚β-环糊精配制的静脉注射伏立康唑的治疗药物监测与安全性
Mycoses. 2016 Oct;59(10):644-51. doi: 10.1111/myc.12517. Epub 2016 Jun 21.
4
Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: A systematic review.基线肾功能损害患者静脉用伏立康唑治疗后肾功能恶化：系统评价。
Int J Antimicrob Agents. 2015 Oct;46(4):362-6. doi: 10.1016/j.ijantimicag.2015.05.023. Epub 2015 Jul 22.
5
Evaluation of intravenous voriconazole in patients with compromised renal function.评估肾功能受损患者的静脉用伏立康唑。
BMC Infect Dis. 2013 Jan 16;13:14. doi: 10.1186/1471-2334-13-14.
6
Investigation of the freely available easy-to-use software 'EZR' for medical statistics.医学统计学中免费易用软件 EZR 的调查研究。
Bone Marrow Transplant. 2013 Mar;48(3):452-8. doi: 10.1038/bmt.2012.244. Epub 2012 Dec 3.
7
Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.基线肾功能不全和念珠菌血症患者中伏立康唑的安全性和耐受性。
Antimicrob Agents Chemother. 2012 Jun;56(6):3133-7. doi: 10.1128/AAC.05841-11. Epub 2012 Mar 26.
8
Administration of voriconazole in patients with renal dysfunction.肾功能障碍患者伏立康唑的给药。
Clin Infect Dis. 2012 Apr;54(7):913-21. doi: 10.1093/cid/cir969. Epub 2012 Jan 19.
9
Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).磺丁基醚-β-环糊精（SBECD）的基础和临床药理学评价。
J Pharm Sci. 2010 Aug;99(8):3291-301. doi: 10.1002/jps.22109.
10
Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.伏立康唑在肾功能受损受试者中的药代动力学、安全性及耐受性：两项前瞻性、多中心、开放标签、平行组志愿者研究
Clin Drug Investig. 2008;28(7):409-20. doi: 10.2165/00044011-200828070-00002.
Zotero 插件